Pharmaceutical company Eli Lilly is getting ready to introduce a new oral weight loss medication in the United States, with plans to potentially launch as early as the second quarter of 2024, pending final regulatory approval.
Lucas Montarce, the company’s Chief Financial Officer, announced Monday that Eli Lilly is moving forward with preparations to bring orforglipron to market once the Food and Drug Administration gives its approval.
Speaking at the TD Cowen healthcare conference, Montarce expressed optimism about the timeline, stating: “On track in the US, expect to see potentially that product coming into the market as early as Q2.”
The announcement comes as demand continues to grow for effective obesity treatments across the country.
